Eyraud A, et al. - Researchers sought to assess the safety and effectiveness of autologous haematopoietic stem cell transplantation (HSCT) in adults with systemic sclerosis (SSc). As per the data, a significant reduction in skin thickening maintained for up to 8 years following HSCT was seen. Lung function demonstrated slight improvement, measured as forced vital capacity, at 1 or 2 years. For disease progression, the death rate attributable was 11%, 8.3% for HSCT and for cyclophosphamide 1%. Taking into account the poor prognosis of this disease, it was concluded that the safety and efficacy of autologous HSCT in SSc are acceptable.